Free Trial

Sonnet BioTherapeutics Q3 2023 Earnings Report

Sonnet BioTherapeutics logo
$1.54 0.00 (0.00%)
As of 01/21/2025 04:00 PM Eastern

Sonnet BioTherapeutics EPS Results

Actual EPS
-$2.86
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Sonnet BioTherapeutics Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sonnet BioTherapeutics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Sonnet BioTherapeutics Earnings Headlines

Sonnet BioTherapeutics expands Phase 1 SB101 trial
Grab This Altcoin Before Trump's Crypto Announcement
Grab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now.
Sonnet BioTherapeutics sees cash runway into July 2025
See More Sonnet BioTherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sonnet BioTherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sonnet BioTherapeutics and other key companies, straight to your email.

About Sonnet BioTherapeutics

Sonnet BioTherapeutics (NASDAQ:SONN), a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

View Sonnet BioTherapeutics Profile

More Earnings Resources from MarketBeat